NTRK1 and cancer: Because NTRK fusion can arise as a mechanism of cancer resistance to other targeted therapies, approaches to overcoming NTRK fusion-based resistance can be used for resistance that develops during combined TRK inhibition-based therapy and the continued inhibition of the original target.